AstraZeneca to Divest its Hypertension Therapies to Atnahs Pharma

 AstraZeneca to Divest its Hypertension Therapies to Atnahs Pharma

AstraZeneca to Divest its Hypertension Therapies to Atnahs Pharma

Shots:

  • AstraZeneca to receive $350M up front, up to $40M as commercial milestones b/w 2020 to 2022. Atnahs to get global commercial rights (Ex- US, India and Japan) of Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone FD combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide FD combination)
  • AstraZeneca will retain rights in Japan and will continue to manufacture & supply the therapies during the transaction period. The divestiture is expected to be completed in Q1’20
  • Inderal and Tenormin are beta-blockers, used to treat angina hypertension and arrhythmias. Zestril is an ACE inhibitor indicated to treat hypertension, CHF, diabetic-related conditions and hypertensive renal disease

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post